Medannex https://validator.w3.org/feed/docs/rss2.html FDA Grants US Orphan Drug Designation to Medannex’s First-in-Class Therapy MDX-124 Innovation About Home page Team Delia Herrington Jen McDowall Scott Crichton Dr Henry Hays James Ingham Dr Fiona Dempsey Ian Abercrombie Prof Christopher Wood Colin Tennant Medannex Unveils Positive Clinical Data on MDX-124 at ESMO 2025 Dr Lisa Yule Medannex Receives Scottish Life Sciences Innovation Award News Medannex unveils novel approach to osteosarcoma treatment at ESMO Meeting Medannex awarded ‘Transforming Cancer Therapeutics’ grant to accelerate new treatment for bone cancer in children Nature publication demonstrates anti-cancer effects of MDX-124 in multiple tumour types Contact Terms of Use Medannex Ltd awarded £423,000 via SMART: SCOTLAND to develop novel antibody Regulators give green light to first-in-human study with MDX-124 Medannex features in global pharmaceutical publication ‘Scrip’ Medannex unveils First-in-Human study of novel cancer therapy at ASCO 2024 Paul Flook Medannex’s First-in-class Therapy Awarded UK ‘Innovation Passport’ to Accelerate Time to Market Medannex Announces First Patient Treated in Phase 1b Clinical Study of Groundbreaking Anti-Annexin-A1 Therapy Publications Medannex Strengthens Global Intellectual Property Portfolio for Novel Clinical Asset Medannex’s first-in-class agent shows significant activity against clinically challenging cancers Medannex’s First-in-Class Therapeutic Granted FDA Orphan Drug Designation for Biliary Tract Cancer MDX-124 receives Orphan Designation from the EMA for the Treatment of Pancreatic Cancer Medannex’s monoclonal antibody MDX-124 highly active in pancreatic cancer models Medannex announces new immunomodulatory approach to cancer treatment at Nature conference Medannex announces Innovate UK grant award for novel cancer therapeutic development Medannex presents data on its immunomodulatory anticancer agent MDX-124 at AACR Annual Meeting Medannex completes final tranche of £11m Series B investment, led by Morningside Venture Capital Medannex chosen by Welp Magazine as a company to watch in the UK Clinical Trials space Medannex team grows to 12 employees, as preparations for First-in-Human study gather pace Medannex sweeps the board at Scotland’s Life Sciences Annual Awards Medannex unveils the multiple anti-cancer effects of MDX-124 at AACR Annual Meeting 2021 Medannex team leads the field in BIA charity fundraiser Medannex’s new therapy shows powerful synergy with common cancer treatments Clinical Studies Sir Graham Brady MP appointed to the board of Medannex Careers Privacy Policy